[go: up one dir, main page]

WO2006105798A3 - Formulation de benzimidazole - Google Patents

Formulation de benzimidazole Download PDF

Info

Publication number
WO2006105798A3
WO2006105798A3 PCT/DK2006/000409 DK2006000409W WO2006105798A3 WO 2006105798 A3 WO2006105798 A3 WO 2006105798A3 DK 2006000409 W DK2006000409 W DK 2006000409W WO 2006105798 A3 WO2006105798 A3 WO 2006105798A3
Authority
WO
WIPO (PCT)
Prior art keywords
dry
manufacturing process
pharmaceutical formulation
benzimidazole
superfluous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/000409
Other languages
English (en)
Other versions
WO2006105798A2 (fr
Inventor
Poul Bertelsen
Peder Mohr Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Priority to EP06753346A priority Critical patent/EP1901719A2/fr
Priority to AU2006230974A priority patent/AU2006230974C1/en
Priority to CA002614526A priority patent/CA2614526A1/fr
Priority to EA200800290A priority patent/EA015535B1/ru
Publication of WO2006105798A2 publication Critical patent/WO2006105798A2/fr
Publication of WO2006105798A3 publication Critical patent/WO2006105798A3/fr
Anticipated expiration legal-status Critical
Priority to NO20080691A priority patent/NO20080691L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de fabrication à sec destiné à la production d'une formulation pharmaceutique d'un benzimidazole et d'une substance alcaline. Un comprimé est comprimé directement à partir d'une poudre sèche ou d'une substance particulaire sèche, contournant ainsi l'utilisation d'un liquide ou excipient quelconque généralement utilisé comme liant humide. Le procédé de fabrication présente un caractère avantageux en ce qu'il est simple et rentable, une étape de séchage onéreuse étant superflue. La formulation pharmaceutique obtenue présente une bonne stabilité et un bon profil de dissolution.
PCT/DK2006/000409 2005-07-11 2006-07-11 Formulation de benzimidazole Ceased WO2006105798A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06753346A EP1901719A2 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole
AU2006230974A AU2006230974C1 (en) 2005-07-11 2006-07-11 Benzimidazole formulation
CA002614526A CA2614526A1 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole
EA200800290A EA015535B1 (ru) 2005-07-11 2006-07-11 Формуляция бензимидазола
NO20080691A NO20080691L (no) 2005-07-11 2008-02-07 Benzimidazole formulation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200501019 2005-07-11
DKPA200501019 2005-07-11
US72785505P 2005-10-19 2005-10-19
US60/727,855 2005-10-19

Publications (2)

Publication Number Publication Date
WO2006105798A2 WO2006105798A2 (fr) 2006-10-12
WO2006105798A3 true WO2006105798A3 (fr) 2006-12-07

Family

ID=37492042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000409 Ceased WO2006105798A2 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole

Country Status (5)

Country Link
EP (1) EP1901719A2 (fr)
AU (1) AU2006230974C1 (fr)
CA (1) CA2614526A1 (fr)
EA (1) EA015535B1 (fr)
WO (1) WO2006105798A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
TR201000948A1 (tr) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
CN103386133A (zh) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 一种质子泵抑制剂的口腔速溶制剂及其制备方法
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
CN104825414B (zh) * 2015-05-07 2018-11-16 山东新时代药业有限公司 一种稳定的s-泮托拉唑钠肠溶片
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
CA3061888A1 (fr) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Traitement du carcinome hepatocellulaire
CN113318079B (zh) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法
CN115645373B (zh) * 2022-12-24 2024-01-30 山东理工职业学院 一种奥美拉唑钠片的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (fr) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
WO2004075881A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2004112756A1 (fr) * 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005009410A2 (fr) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Compositions pharmaceutiques a revetement gonflant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050019A1 (fr) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Formes posologiques pharmaceutiques orales stables
EP1004305A1 (fr) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
WO2004075881A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2004112756A1 (fr) * 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005009410A2 (fr) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Compositions pharmaceutiques a revetement gonflant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1901719A2 *

Also Published As

Publication number Publication date
EA015535B1 (ru) 2011-08-30
AU2006230974B2 (en) 2011-09-29
WO2006105798A2 (fr) 2006-10-12
CA2614526A1 (fr) 2006-10-12
AU2006230974C1 (en) 2012-02-02
EA200800290A1 (ru) 2008-08-29
EP1901719A2 (fr) 2008-03-26
AU2006230974A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006105798A3 (fr) Formulation de benzimidazole
NO20035654D0 (no) System for avlevering av törrpulverformuleringer
IL163642A0 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ITBO20010082A0 (it) Macchina comprimitrice per la produzione di compresse
SI1689370T2 (sl) Postopek za pripravo trdnega, oralno uporabnega farmacevtskega sestavka, ki obsega 5-klor-N(((5S)-2okso-3-(4-(3-okso-4-morfolinil)-fenil)-1,3-oksazolidin -5-il)-metil)-2-tiofenkarboksamid
NO20014835L (no) Fremgangsmate for fremstilling av monodisperse polymerpartikler
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
WO2005112897A3 (fr) Tablettes pharmaceutiques a liberation immediate plus hautes que larges
ITBO20010141A0 (it) Macchina comprimitrice per la produzione di compresse
IL156803A0 (en) Coated barium titanate-based particles and process for the production thereof
WO2010116223A3 (fr) Procédé de fabrication d'un récipient en papier
NO20062795L (no) Fremgangsmate for fremstilling av granulaere sjokoladebasematerialer for sjokoladeproduksjon og produkter derav
NO20080691L (no) Benzimidazole formulation
NL1013849A1 (nl) Werkwijze voor het vervaardigen van verpoederd uitgangsmateriaal voor diëlektrische keramiek.
ZA200810345B (en) Process for preparing spray dried formulations of tmc125
ITBO20040014A1 (it) Macchina comprimitrice per la produzione di compresse
IL200447A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
NO20042022L (no) Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen
PT1819320E (pt) Composição farmacêutica dispersável oralmente e processo para a sua preparação
EP2907636A1 (fr) Procédé de production de structure en nid d'abeilles
EP1840103A3 (fr) Procédé de production d'un corps dense fritté de céramique en forme d'une feuille
WO2007072497A3 (fr) Composition pharmaceutique stabilisée de pramipexole et son procédé de préparation
EP1954246A4 (fr) Composition pharmaceutique solide comprenant des nanoparticles d agglomerat et leur procede de production
PL378157A1 (pl) Półpłynna kompozycja farmaceutyczna na bazie metylocelulozy i sposób otrzymywania półpłynnej kompozycji farmaceutycznej na bazie metylocelulozy
UA40999A (uk) Спосіб одержання твердої фармацевтичної композиції

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753346

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2614526

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006230974

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2006230974

Country of ref document: AU

Date of ref document: 20060711

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006230974

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200800290

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006753346

Country of ref document: EP